Literature DB >> 26071048

Cognitive Adverse Effects of Antiepileptic Drugs : Incidence, Mechanisms and Therapeutic Implications.

R Kälviäinen1, M Äikiä, P J Riekkinen.   

Abstract

Several early studies suggested that differences exist between antiepileptic drugs (AEDs) in terms of their propensity to cause adverse effects on cognitive functions, favouring carbamazepine over phenobarbital (phenobarbitone), phenytoin and valproic acid (sodium valproate). The combined results of recent studies in patients and healthy volunteers reveal that at therapeutic serum concentrations phenobarbital, phenytoin, carbamazepine, oxcarbazepine and valproic acid produce nearly comparable adverse effects on higher cognitive functions.The newer AEDs (with the exception of zonisamide and topiramate) appear to induced fewer cognitive adverse effects than the older agents. Furthermore, there is limited evidence that gabapentin, lamotrigine and vigabatrin may have beneficial effects on cognitive function. Some of the newer AEDs may also have neuroprotective effects that can prevent seizure-induced neuronal damage, and so reduce cognitive dysfunction. This is an important clinical consideration, as even modest differences between older and newer AEDs are relevant for patients.

Entities:  

Year:  1996        PMID: 26071048     DOI: 10.2165/00023210-199605050-00005

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  69 in total

1.  Zonisamide (CI-912) and cognition: results from preliminary study.

Authors:  S Berent; J C Sackellares; B Giordani; J G Wagner; P D Donofrio; B Abou-Khalil
Journal:  Epilepsia       Date:  1987 Jan-Feb       Impact factor: 5.864

2.  Tiagabine prevents seizures, neuronal damage and memory impairment in experimental status epilepticus.

Authors:  T Halonen; J Nissinen; J A Jansen; A Pitkänen
Journal:  Eur J Pharmacol       Date:  1996-03-28       Impact factor: 4.432

3.  Verbal learning and memory in newly diagnosed partial epilepsy.

Authors:  M Aikiä; R Kälviäinen; P J Riekkinen
Journal:  Epilepsy Res       Date:  1995-10       Impact factor: 3.045

4.  Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy.

Authors:  C B Dodrill; J L Arnett; K W Sommerville; N M Sussman
Journal:  Neurology       Date:  1993-12       Impact factor: 9.910

5.  Glycine-induced CA1 excitotoxicity in the rat hippocampal slice.

Authors:  R A Wallis; K L Panizzon; J P Nolan
Journal:  Brain Res       Date:  1994-11-21       Impact factor: 3.252

6.  Neuroprotective effect of remacemide hydrochloride in focal cerebral ischemia in the cat.

Authors:  P E Bannan; D I Graham; K R Lees; J McCulloch
Journal:  Brain Res       Date:  1994-11-21       Impact factor: 3.252

Review 7.  Oxcarbazepine. A review of its pharmacology and therapeutic potential in epilepsy, trigeminal neuralgia and affective disorders.

Authors:  S M Grant; D Faulds
Journal:  Drugs       Date:  1992-06       Impact factor: 9.546

8.  Neuroprotective effect of felbamate after kainic acid-induced status epilepticus.

Authors:  A Chronopoulos; C Stafstrom; S Thurber; P Hyde; M Mikati; G L Holmes
Journal:  Epilepsia       Date:  1993 Mar-Apr       Impact factor: 5.864

9.  Psychotropic effects of carbamazepine in epilepsy: a double-blind comparison with phenytoin.

Authors:  C B Dodrill; A S Troupin
Journal:  Neurology       Date:  1977-11       Impact factor: 9.910

10.  Neurobehavioral effects of phenytoin and carbamazepine in patients recovering from brain trauma: a comparative study.

Authors:  K R Smith; P M Goulding; D Wilderman; P R Goldfader; P Holterman-Hommes; F Wei
Journal:  Arch Neurol       Date:  1994-07
View more
  5 in total

Review 1.  Anticonvulsants and breast feeding: a critical review.

Authors:  B Bar-Oz; I Nulman; G Koren; S Ito
Journal:  Paediatr Drugs       Date:  2000 Mar-Apr       Impact factor: 3.022

2.  The tolerability of lamotrigine in elderly patients with epilepsy.

Authors:  L Giorgi; G Gomez; F O'Neill; A E Hammer; M Risner
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 3.  CNS adverse events associated with antiepileptic drugs.

Authors:  Gina M Kennedy; Samden D Lhatoo
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 4.  Topiramate. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy.

Authors:  H D Langtry; J C Gillis; R Davis
Journal:  Drugs       Date:  1997-11       Impact factor: 9.546

Review 5.  Topiramate: a review of its use in childhood epilepsy.

Authors:  D Ormrod; K McClellan
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.930

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.